SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing intense selling pressure following a quarterly report that revealed significant headwinds in China and ongoing concerns regarding the impact of tariffs on margins. Investors are actively debating the company's long-term relevance and the effectiveness of management's turnaround efforts, with many expressing frustration over the stock's persistent decline compared to its historical performance.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for community discussion as investors debate its long-term potential amid significant leadership changes and a shift toward U.S.-based institutional operations. While some users express frustration over stagnant price action and recent market lows, a vocal segment of the community remains focused on the project's real-world utility, recent regulatory clarity, and its ongoing efforts to scale institutional adoption.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF (NASA) is drawing significant attention as traders debate whether its small asset base and exposure to SpaceX represent a promising new momentum play or a potential risk. Community discussion is sharply divided, with some investors eyeing the ticker for its high-volatility potential and similarities to recent thematic ETF surges, while others express skepticism over its low assets under management and limited holdings.

Ganymede

Ganymede is drawing attention as market participants highlight its clean structural formation and consistent buyer interest, fueling community optimism about its potential for growth. Traders are actively discussing the token's quiet momentum and controlled price action, viewing current levels as a favorable accumulation phase.

Maul Coin

Maul Coin is trending as the community rallies around a creator-backed project, actively promoting it across social platforms to drive volume and secure a listing. Supporters are focused on organic growth and the potential for a community-led breakout, while closely monitoring market activity following recent whale selling.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest the commercial launch of Yartemlea following recent FDA approval and look ahead to upcoming earnings for initial revenue insights. Community discussion remains focused on the company's strong cash position, the strategic potential of the Novo Nordisk partnership, and anticipation of a potential squeeze as market participants weigh long-term value against ongoing short interest.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is experiencing intense volatility as investors debate the impact of conflicting geopolitical headlines, specifically regarding potential military escalation in the Middle East and market manipulation concerns. Community sentiment is deeply divided, with traders actively weighing the risk of a market-wide correction against the effectiveness of current government-led de-escalation narratives.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is seeing intense community debate as investors weigh its status as a battle-tested DeFi protocol against significant price volatility and concerns over governance efficacy. While some holders point to a capped supply and potential for V4 protocol updates as a catalyst for a rebound, many participants are expressing frustration over persistent downward pressure and are actively comparing its performance to competitors like AAVE.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

The GEO Group is seeing heightened investor attention driven by expectations of expanded government detention contracts and increased deportation enforcement under the current administration. While some community members voice concerns over sector ethics and legislative scrutiny, bullish investors are focused on the company's real estate assets, institutional positioning, and potential for growth as ICE scales operations and seeks additional facility capacity.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is facing heightened scrutiny and volatility ahead of its earnings release, with community sentiment deeply divided between investors betting on a potential short squeeze fueled by deep undervaluation and bears citing concerns over management's compensation, debt, and the 'value trap' narrative. The discourse is dominated by anticipation for the company's path toward profitability, with shareholders actively debating whether recent leadership changes and strategic focus on international growth can trigger a reversal in the long-term downward price trend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 12-Month High - Here's Why

Edgewise Therapeutics (NASDAQ:EWTX) Hits New 12-Month High - Still a Buy...

Why Edgewise Therapeutics Stock Topped the Market on Tuesday

Key PointsShe raised her price target by $11 per share...

JPMorgan Chase & Co. Raises Edgewise Therapeutics (NASDAQ:EWTX) Price Target to $45.00

JPMorgan Chase & Co. upped their target price on Edgewise Therapeutics from $34.00 to $45.00 and gave the company an "overweight" rating in a research report on Tuesday...

Edgewise Therapeutics, Inc. $EWTX Shares Purchased by HighVista Strategies LLC

HighVista Strategies LLC grew its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 198.5% during the 3rd quarter, according to its most recent 13F filing with the...

First Light Asset Management LLC Lowers Stock Holdings in Edgewise Therapeutics, Inc. $EWTX

First Light Asset Management LLC cut its holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 17.4% in the third quarter, according to its most recent disclosure with the Securities...

Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference

Executives from Edgewise Therapeutics (NASDAQ:EWTX) highlighted recent clinical updates and upcoming milestones across the company's neuromuscular and cardiovascular pipeline during a discussion...

American Century Companies Inc. Buys 312,307 Shares of Edgewise Therapeutics, Inc. $EWTX

American Century Companies Inc. grew its stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 39.9% in the 3rd quarter, according to its most recent disclosure with the SEC...

Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up Edgewise Announces Positive...

Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 PR...

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference Edgewise Therapeutics to Present on Sevasemten for the...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Edgewise Therapeutics Inc

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

EWTX
Edgewise Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EWTX News

EWTXEdgewise Therapeutics Inc